Cargando…

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

On the occasion of its recent approval for relapsed follicular lymphoma, we review the design and development of the pan-class I PI3K inhibitor copanlisib as a drug for the treatment of B-cell malignancies in comparison with other kinase inhibitors targeting B-cell-receptor signaling, in particular...

Descripción completa

Detalles Bibliográficos
Autores principales: Krause, Günter, Hassenrück, Floyd, Hallek, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109662/
https://www.ncbi.nlm.nih.gov/pubmed/30174412
http://dx.doi.org/10.2147/DDDT.S142406